This is an old revision of this page, as edited by Dclutz (talk | contribs) at 03:36, 1 June 2013 (Undid revision 556216027 by LFaraone (talk)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 03:36, 1 June 2013 by Dclutz (talk | contribs) (Undid revision 556216027 by LFaraone (talk))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | |
| Company type | Public |
|---|---|
| Traded as | Nasdaq: ANTH |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
| Key people | Paul F. Truex (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, Immunoglobin A nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.
Product Candidates
- Blisibimod, an investigational anti-BAFF molecule in Phase III trails for the treatment of systemic lupus erythematosus and Phase II trials for the treatment of IgA nephropathy.
References
- . U.S. Securities and Exchange Commission. March 26, 2012 10-K, Anthera Pharmaceuticals, Inc. http://investor.anthera.com/secfiling.cfm?filingID=1214659-13-1633=Form 10-K, Anthera Pharmaceuticals, Inc.
{{cite web}}: Check|url=value (help); Missing or empty|title=(help)
